Febuxostat

非布司他

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameFebuxostat
Drug Alias Name非布索坦febuxostatum菲索司他非布佐司他风定宁 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionXanthine dehydrogenase inhibitors
TargetsXanthine dehydrogenase
Therapy Area/IndicationsPainHyperuricemiaTumor Lysis Syndrome +[13] 
Global Approved IndicationsHyperuricemiaGout
Approved Indications in ChinaHyperuricemiaGout
Original Approved Country/TerritoryEU
Original Approved Date2008/04/21
Country/TerritoryBulgariaUnited StatesTaiwan +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTeijin Pharma
China Registration ClassN/A

Develop Information

Active CompaniesBio-innova Co LtdTakeda Pharmaceuticals USA IncTanta University +[7] 
Inactive CompaniesMenarini GroupAstellas Pharma Taiwan IncTakeda Pharmaceutical Co Ltd +[28] 
Active IndicationsPainHyperuricemiaRenal Insufficiency, Chronic +[5] 
Inactive IndicationsTumor Lysis SyndromeHypertensionVascular Diseases +[8] 

Other Information

ATC CodeM04AA03
Related LinksWikipediaDrugBankKEGG